Trovagene (TROV) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Jaffray Cuts Price Target on Trovagene (TROV) Following 1Q Miss
May 11, 2016 8:06 AM EDTPiper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $5.00 (from $8.00), following the company's 1Q earnings report. Trovagene reported revenue of $120K, well below the Street's ~$280K estimate. Adjusted EPS of ($0.36) was $0.07 below the Street estimate of ($0.29).
Analyst... More
